Bharat Biotech inks licensing deal with Washington University School of Medicine for Covid-19 intranasal vaccine technology

V Rishi Kumar Hyderabad | Updated on September 23, 2020 Published on September 23, 2020

Krishna Ella, Chairman and Managing Director, Bharat Biotech   -  Nagara Gopal@thehindu

Company owns the rights to distribute the vaccine in all markets except the US, Japan and Europe

Vaccine Innovator Bharat Biotech has announced a licensing agreement with Washington University School of Medicine for a novel chimp-adenovirus, single dose intranasal vaccine for Covid-19.

Bharat Biotech owns the rights to distribute the vaccine in all markets except USA, Japan and Europe.

While the Phase I trials will take place in Saint Louis University’s Vaccine & Treatment Evaluation Unit, Bharat Biotech, upon obtaining the required regulatory approval, will pursue further stages of clinical trials in India and undertake large scale manufacture of the vaccine at its GMP facility in Genome Valley, Hyderabad.

Diverse projects

“We are proud to collaborate on this innovative vaccine. We envision that we will scale this vaccine to 1 billion doses, translating to 1 billion individuals vaccinated receiving a single-dose regimen. An intranasal vaccine will not only be simple to administer but reduce the use of medical consumables such as needles, syringes, significantly impacting the overall cost of a vaccination drive. Our experience in viral vaccines, manufacturing capabilities, and distribution continue to be our strong suit in ensuring safe, efficacious, and affordable vaccines. It is prudent for Bharat to be involved in diverse but tenable projects to provide a much-needed vaccine against Covid-19 reaches all citizens of the world,” Krishna Ella, Chairman and Managing Director of Bharat Biotech, said.

This intranasal vaccine candidate has shown unprecedented levels of protection in mice studies; the technology and data having been recently published in the prestigious scientific journal Cell and in an editorial in Nature.

Advantage of single nasal dose

David T Curiel, MD, Director of Biologic Therapeutics Center and Professor of Radiation Oncology at Washington University School of Medicine in St Louis and Precision Virologics Interim CEO said, “The ability to accomplish effective immunisation with a single nasal dose is a major advantage, offering broader reach and easier administration. An effective nasal dose not only protects against Covid-19, but it also prevents the spread of the disease by offering another kind of immunity that occurs primarily in the cells that line the nose and throat. Most other vaccine candidates currently under development can’t do that.”

This vaccine expands Bharat’s portfolio of vaccines that are currently being developed and are in various stages of clinical development including Covaxin which is currently in Phase II human clinical trials in India.

Also read: Bharat Biotech’s Covaxin shows protective efficacy, immunogenicity in non-human primates

Also read: DCGI approves Bharat Biotech’s Covid-19 vaccine for human clinical trials

Bharat Biotech has more than 140 global patents, a wide product portfolio of more than 16 vaccines, four bio-therapeutics, registrations in more than 116 countries and WHO Pre-qualifications.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on September 23, 2020
This article is closed for comments.
Please Email the Editor